A cell line that maintains favorable growth and productivity characteristics is vital for biopharmaceutical manufacturing processes, whether you are producing monoclonal antibodies, recombinant proteins, or viral vectors for gene therapies. Our ready-to-use cell line systems can accelerate your upstream development by greatly reducing the time, cost, and risk of developing new cell lines. Our cell lines are rationally engineered and designed for compliant biomanufacturing.
Key features include:
Flyer: Sf-RVN® Platform
Product Information Sheet: Sf-RVN® Insect Cell Line
Product Information Sheet: EX-CELL® CD Insect Cell Medium
White Paper: Development of a Novel Sf9 Rhabdovirus-Negative Cell Line (Sf-RVN®) and Companion Chemically Defined Medium
Poster: Explore Performances of the EX-CELL® CD Insect Cell Medium
Webinar: Addressing the Challenge of Scalability in Viral Vectors
Webinar: Risk Mitigation in Cell Line Development: Regulatory Considerations and Impact on Quality Assurance
White Paper: Considerations for Bioreactor Process Development and Scale-up for Transient Transfection-based Lentivirus Production in Suspension
White Paper: A Multifaceted Strategy for Viral Safety in AAV Processes
The majority of Spodoptera frugiperda cells (such as Sf9) contain a rhabdovirus that is considered a process contaminant and must be eliminated during the bioprocess.
Our Sf-RVN® Platform offers a rhabdovirus-free alternative for bioprocesses and enhances risk mitigation.
The Sf-RVN® Platform is a synergy between a Sf9 rhabdovirus-negative cell line with companion chemically defined medium, specifically formulated to get excellent growth and productivity of the cell line.
Combined, the Sf-RVN® Insect Cell Line with companion EX-CELL® CD Insect Cell Medium provide a high performant platform optimal to produce recombinant proteins, viral vaccines such as viral like particles (VLP) and adeno-associated vectors (AAV) for gene therapy applications.
For more information on the Sf-RVN® Insect Cell Line or to order, please click here.
Our CHOZN® platform is a Chinese Hamster Ovary (CHO) mammalian cell expression system that allows for faster, simpler selection and scale-up of high-producing clones for production of biologics and therapeutic recombinant proteins. It includes:
Three CHOZN® cell lines are available:
Powered by CompoZr® Zinc Finger Nuclease (ZFN) technology, the well-known and widely adopted CHOZN® GS-/- cell line can help shorten cell line development time lines by up to eight weeks while ensuring excellent stability, with >75% of clones maintaining >70% titer of 60 generations.
Optimized expression vectors for the CHOZN® GS -/- cell line include:
Our VirusExpress™ platform offers a transfection-based solution for lentiviral (LV) production challenges, featuring a suspension adapted cell line, chemically defined medium, and process with proven performance at clinically relevant scale. The platform can dramatically reduce time in process development and scale-up, either within your own facilities or using our contract manufacturing capabilities to speed your therapy to patients. Attributes include:
VirusExpress™ 293T Lentiviral Production Cells are optimized for production of lentiviral vectors for gene therapy applications. Comprehensive user protocols guide you from seed train through at-scale transfection and virus production, allowing seamless scale-up. Robust quality documentation enables regulatory filings and commercialization of your gene-modified cell therapy.